Functional‑medicine expert Dr. Will Cole told Fox News Digital that while peptide‑based medications such as GLP‑1 agonists can aid weight loss, taking them at very high doses is comparable to setting off an “atomic bomb” in the body’s hunger‑signaling system.
Peptides and metabolic health
Cole, co‑author of the forthcoming book Heal Your Cells, explained that peptides are “intimately connected” to longevity, cellular healing and metabolic health. He emphasized that peptides help with cellular communication, but the appropriate dose often lies “somewhere in the middle.”
Referencing research that suggests roughly 93% of U.S. adults are metabolically unhealthy, Cole described the 7% who meet optimal metabolic standards as a “wild” minority. He noted that while GLP‑1 medications can reduce food cravings—what he calls “food noise”—they are not a cure‑all.
Risks of “macro‑dosing”
According to Cole, “macro‑dosing” GLP‑1 drugs “forever and ever in perpetuity” is not the solution. He warned that excessively suppressing hunger cues could have unintended consequences for other reward‑related behaviors, including social relationships and emotional well‑being. “Are we circumventing pathways and pathologizing things that don’t have to be pathologized?” he asked.
He argued that some degree of hunger signaling is healthy. “Food noise is actually a decent thing in balance, so shutting down your hunger cues with an ‘atomic bomb’ peptide dose is not the solution,” Cole said.
Balancing medication with lifestyle
Cole stressed that overreliance on GLP‑1 drugs may foster disordered eating patterns and a growing fear of hunger. He attributed the trend to a culture that prefers quick, pharmaceutical fixes over sustained lifestyle changes, noting, “We want a magic pill.”
He suggested a more measured approach: “Can we micro‑dose? Can we do it cyclically? And can we pair it with lifestyle?” He believes the lowest effective dose, combined with proper diet, exercise and stress management, is where peptides can truly shine.
Potential broader benefits
Despite his cautions, Cole remains optimistic about the therapeutic promise of GLP‑1 medications. He cited emerging evidence that these drugs may reduce inflammation, help manage autoimmune conditions and improve gut health.
He also expressed excitement about other peptide classes, such as those targeting inflammation and longevity, saying, “I am actually more excited about some of these other peptides, like the inflammation ones or the longevity peptides.”
Call for transparency
Finally, Cole advocated for wider access to peptide therapies, but only if products are transparent, pure and clearly labeled. He believes informed consumers and healthcare professionals can make better decisions when they know exactly what they are taking.
Original reporting: Fox News (HLL/CB) — read the source article.
